Sartorius has supported CanSino Biologics Inc. and the Institute of Bioengineering in China in their development of the first vaccine candidate against the novel coronavirus to enter clinical trials. CanSinoBIO and the Institute of Bioengineering used Sartorius’ BIOSTAT STR single-use bioreactor system for the upstream preparation of the recombinant vaccine, and rapid linear amplification of the adenovirus vector (Ad5-nCoV). The BIOSTAT STR single-use bioreactor system comes with updat...